Last reviewed · How we verify

NCT02875678

A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia

Terminated Phase 1 Last updated 7 September 2017
What this trial tests

Phase 1 trial testing ABX-1431 in Dyspepsia in 4 participants. Terminated before completion.

Timeline
22 November 2016
Primary endpoint
7 August 2017
7 August 2017

Quick facts

Lead sponsorAbide Therapeutics
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposebasic science
Enrollment4
Start date22 November 2016
Primary completion7 August 2017
Estimated completion7 August 2017
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Abide Therapeutics — full company profile →

Who can join

Adults 18 to 65, any sex, with Dyspepsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients with Functional Dyspepsia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ABX-1431

Trials testing the same drug.

Other recruiting trials for Dyspepsia

Currently open trials in the same condition.

Other Abide Therapeutics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02875678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing